Search hospitals > Minnesota > Minneapolis
Hennepin County Medical Center
Claim this profileMinneapolis, Minnesota 55415
Global Leader in Cancer
Global Leader in Breast Cancer
Conducts research for Lung Cancer
Conducts research for Non-Small Cell Lung Cancer
Conducts research for Adenocarcinoma
682 reported clinical trials
23 medical researchers
Summary
Hennepin County Medical Center is a medical facility located in Minneapolis, Minnesota. This center is recognized for care of Cancer, Breast Cancer, Lung Cancer, Non-Small Cell Lung Cancer, Adenocarcinoma and other specialties. Hennepin County Medical Center is involved with conducting 682 clinical trials across 725 conditions. There are 23 research doctors associated with this hospital, such as David M. King, Daniel M. Anderson, Yan Ji, and Pamala A. Pawloski.Area of expertise
1Cancer
Global LeaderStage IV
Stage III
Stage II
2Breast Cancer
Global LeaderHER2 negative
ER positive
Stage IV
Top PIs
David M. KingRegions Hospital7 years of reported clinical research
Expert in Cancer
Expert in Lung Cancer
91 reported clinical trials
154 drugs studied
Daniel M. AndersonAbbott-Northwestern Hospital4 years of reported clinical research
Expert in Cancer
Expert in Tumors
59 reported clinical trials
107 drugs studied
Yan JiRegions Hospital1 year of reported clinical research
Expert in Cancer
Studies Breast Cancer
29 reported clinical trials
72 drugs studied
Pamala A. PawloskiPark Nicollet Clinic - Saint Louis Park5 years of reported clinical research
Studies Cancer
Studies Tumors
14 reported clinical trials
19 drugs studied
Clinical Trials running at Hennepin County Medical Center
Breast Cancer
Esophageal Adenocarcinoma
Gastroesophageal Junction Adenocarcinoma
Prostate Cancer
Cancer
Esophageal Carcinoma
Lung Cancer
Non-Small Cell Lung Cancer
Gastric Cancer
Esophageal Cancer
Chemotherapy + Hormone Therapy
for Breast Cancer
This Phase III Trial will determine whether adjuvant chemotherapy (ACT) added to ovarian function suppression (OFS) plus endocrine therapy (ET) is superior to OFS plus ET in improving invasive breast cancer-free survival (IBCFS) among premenopausal, early- stage breast cancer (EBC) patients with estrogen receptor (ER)-positive, HER2-negative tumors and 21-gene recurrence score (RS) between 16-25 (for pN0 patients) and 0-25 (for pN1 patients).
Recruiting2 awards Phase 319 criteria
Durvalumab + Chemotherapy
for Breast Cancer
This phase III trial compares the addition of an immunotherapy drug (durvalumab) to usual chemotherapy versus usual chemotherapy alone in treating patients with MammaPrint Ultrahigh (MP2) stage II-III hormone receptor positive, HER2 negative breast cancer. Immunotherapy with monoclonal antibodies, such as durvalumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Chemotherapy drugs, such as paclitaxel, doxorubicin, and cyclophosphamide work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. There is some evidence from previous clinical trials that people who have a MammaPrint Ultrahigh Risk result may be more likely to respond to chemotherapy and immunotherapy. Adding durvalumab to usual chemotherapy may be able to prevent the cancer from returning for patients with MP2 stage II-III hormone receptor positive, HER2 negative breast cancer.
Recruiting2 awards Phase 340 criteria
Shorter Chemo-Immunotherapy Without Anthracyclines
for Breast Cancer
This phase III trial compares the effects of shorter chemotherapy (chemo)-immunotherapy without anthracyclines to usual chemo-immunotherapy for the treatment of early-stage triple negative breast cancer. Paclitaxel is in a class of medications called anti-microtubule agents. It stops cancer cells from growing and dividing and may kill them. Carboplatin is in a class of medications known as platinum-containing compounds. It works in a way similar to the anticancer drug cisplatin, but may be better tolerated than cisplatin. Carboplatin works by killing, stopping or slowing the growth of cancer cells. Cyclophosphamide is in a class of medications called alkylating agents. It works by damaging the cell's deoxyribonucleic acid (DNA) and may kill cancer cells. It may also lower the body's immune response. Docetaxel is in a class of medications called taxanes. It stops cancer cells from growing and dividing and may kill them. Doxorubicin is an anthracycline chemotherapy drug that damages DNA and may kill cancer cells. Pembrolizumab may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Shorter treatment without anthracycline chemotherapy may work the same as the usual anthracycline chemotherapy treatment for early-stage triple negative breast cancer.
Recruiting2 awards Phase 347 criteria
Similar Hospitals nearby
Frequently asked questions
What kind of research happens at Hennepin County Medical Center?
Hennepin County Medical Center is a medical facility located in Minneapolis, Minnesota. This center is recognized for care of Cancer, Breast Cancer, Lung Cancer, Non-Small Cell Lung Cancer, Adenocarcinoma and other specialties. Hennepin County Medical Center is involved with conducting 682 clinical trials across 725 conditions. There are 23 research doctors associated with this hospital, such as David M. King, Daniel M. Anderson, Yan Ji, and Pamala A. Pawloski.
Where is Hennepin County Medical Center located?
**Hennepin County Medical Center Location and Parking:**
- Located at 701 Park Avenue, downtown Minneapolis.
- Accessible via Blue or Green Light Rail line to the Government Plaza station, a 4-minute walk away.
- Parking available at HCMC Parking Ramp (6th Street and Park Avenue) or Hospital Parking Ramp (8th Street and Chicago Avenue).
Who should I call to ask about financial aid or insurance network?
**Financial Assistance at Hennepin County Medical Center:**
- For guidance with financial assistance, contact Change Healthcare at the Clinic & Specialty Center, Whittier Clinic, or Brooklyn Park Clinic.
- For insurance inquiries, call the Customer Service Department at 612-873-3073.
- For general billing concerns, also dial 612-873-3073.
- For cash, food, or medical assistance, reach out to the EZ Info line at 612-596-1300.
What insurance does Hennepin County Medical Center accept?
Hennepin County Medical Center, known as Hennepin Healthcare, accepts a wide range of insurance plans. This includes Original Medicare, Medicare Advantage plans such as HumanaChoice (PPO), UCare Prime (HMO-POS), and Medica Advantage (PPO), along with all Medicare Supplemental Plans. They also accept numerous commercial plans, including but not limited to Americas PPO, Blue Cross Blue Shield Aware, Cigna LifeSOURCE Transplant [Kidney], HealthPartners/Cigna Alliance, Medica Passport, PreferredOne PPO, UCare Connect, and UnitedHealthcare Plans. It is recommended to contact Hennepin Healthcare directly to verify network participation and plan acceptance.
What awards or recognition has Hennepin County Medical Center received?
Hennepin County Medical Center (HCMC) in Minneapolis, Minnesota, is nationally recognized for its advancements in health equity by the National Committee for Quality Assurance (NCQA). The Hennepin Healthcare Research Institute (HHRI) enhances patient care through research since 1952, concentrating on Acute Care/Trauma, Addiction, Health Services, and Infectious Diseases (HIV/AIDS).